NEW YORK, September 04, 2012 –Marketsareopen, one of the leaders in providing investment alerts on U.S. stocks are announcing Investment Highlights on top healthcare and biotech stocks including StemCells, Arena Pharmaceuticals, Dendreon, Complete Genomics, Idenix.
StemCells, Inc. (NASDAQ:STEM) stock surged 19.31% to $2.57 after the company announced that interim six-month data from the first patient cohort in the Company's Phase I/II clinical trial of its proprietary HuCNS-SC product candidate (purified human neural stem cells) for chronic spinal cord injury continues to demonstrate a favorable safety profile, and shows considerable gains in sensory function in two of the three patients compared to pre-transplant baselines.
Can Investors Buy STEM Now? If yes, How Far It can Go? Find Out here http://marketsareopen.com/reports/index.php?company=STEM
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) shares gained 0.22% to $9.06 in the morning hour. The company is scheduled to present corporate updates at the Stifel Nicolaus Healthcare Conference Presentation on September 6, 2012, at 9:10 a.m. Eastern Time (6:10 a.m. Pacific Time) at the Four Seasons Hotel in Boston, Massachusetts Presenting: Robert E. Hoffman, Senior Vice President, Finance and Chief Financial Officer.
Can ARNA Bounce Back To New Highs? Find Out Here http://marketsareopen.com/reports/index.php?company=ARNA
Dendreon Corporation (NASDAQ:DNDN) stock increased 1.34% to $4.55 after an analysts at Baird said that Dendreon's prostate cancer drug Provenge continues to underwhelm, but the game is still far from over. Additionally, the firm maintained their Neutral rating and price target of $7.00. The company is a biotechnology company focused on the discovery, development and commercialization of therapeutics that may improve cancer treatment options for patients.
How Should Investors Trade DNDN Now? Get Special Trend Analysis Here http://marketsareopen.com/reports/index.php?company=DNDN
Complete Genomics, Inc. (NASDAQ:GNOM) stock fell 1.64% to $2.99 in the early hour. The 52 week trading range for the company is $1.57 - $9.26. The shares of the company declined 64.45% in the last one year. The company is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform.
Can GNOM Bounce Back? Don’t Forget To Sign Up For Free Here http://marketsareopen.com/reports/index.php?company=GNOM
Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX) shares increased 1.06% to $5.71. The company said U.S. regulators delayed study of one of its medications after a patient taking a competing therapy died from heart failure. Idenix hadn’t yet begun testing IDX19368 in humans. A more advanced drug, IDX184, was suspended in trials Aug. 16.
How Should Investors Trade IDIX Now? Get Special Trend Analysis Here http://marketsareopen.com/reports/index.php?company=IDIX
About Marketsareopen
Marketsareopen’s team is engaged in providing valuable and updated news information on U.S. stocks on a regular basis. Marketsareopen’s instant stock news on Major Gainers, Hot Stocks and various other stocks, guides investors in making the wise stock market investments decision. To Get Instant updates in the inbox, readers are advised to sign up for free at Marketsareopen.com.
Disclaimer:
The assembled information disseminated by marketsareopen.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. marketsareopen.com does expect that investors will buy and sell securities based on information assembled and presented in beststocksdaily.com. PLEASE always do your own due diligence, and consult your financial advisor.
Contacts:
Marketsareopen
1419 Westwood Blvd Los Angeles, CA
90024-4911
staff@ TheMarketsAreOpen.com
www.marketsareopen.com